Clearmind Medicine announced receipt of a Staff Delisting Determination from the Listing Qualifications Department of the Nasdaq Stock Market, LLC. The company was notified that Nasdaq has determined to delist the company’s securities from the Nasdaq Capital Market for failure to maintain a minimum bid price of $1.00 per share for thirty consecutive business days in accordance with Nasdaq Listing Rule 5550(a)(2). The company plans to appeal the Staff’s determination to a Hearings Panel. A hearing request will stay the suspension of the company’s securities and the filing of the Form 25-NSE pending the panel’s decision.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CMND:
- Clearmind Medicine Announces Receipt of Nasdaq Delisting Notice and Plan for Immediate Recompliance
- Clearmind Medicine Announces Shareholders Meeting Results
- Clearmind Medicine announces results of shareholders meeting
- Clearmind Medicine to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League Universities
- Clearmind Medicine enters clinical trial agreement with Johns Hopkins